Loading...
•
Apr 02, 2022
Thermo Fisher Q1 2022 Earnings Report
Thermo Fisher Scientific reported strong financial results for Q1 2022, marked by significant organic growth and strategic advancements.
Key Takeaways
Thermo Fisher Scientific reported a 19% increase in revenue to $11.82 billion for the first quarter of 2022. The company's GAAP diluted EPS was $5.61, and adjusted EPS was $7.25. Core organic growth reached 16%, driven by strong performance in the PPD clinical research business and COVID-19 testing revenue of $1.68 billion.
Revenue grew by 19% to $11.82 billion, with 16% core organic growth.
GAAP diluted EPS was $5.61, and adjusted EPS was $7.25.
Launched new products including the Applied Biosystems SeqStudio Flex Series genetic analyzer and the Thermo Scientific TRACE 1600 Series Gas Chromatograph.
Expanded bioproduction capacity and signed a 15-year strategic collaboration agreement with Moderna.
Thermo Fisher
Thermo Fisher
Thermo Fisher Revenue by Segment
Revenue by Segment
Life Sciences Solutions Revenue
CapyFin.comAnalytical Instruments Revenue
CapyFin.comSpecialty Diagnostics Revenue
CapyFin.comLaboratory Products and Biopharma Services Revenue
CapyFin.com Forward Guidance
The company will provide updated 2022 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Daylight Time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income